Last reviewed · How we verify
NCT04702074
TCM Syndrome Differentiation Treatment on Discharged Elderly Patients With CAP
NA trial testing Traditional Chinese medicine granules in Community-acquired Pneumonia in 292 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Henan University of Traditional Chinese Medicine |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 292 |
| Start date | 15 January 2021 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Traditional Chinese medicine granules
- Traditional Chinese medicine granules placebo
Conditions studied
- Community-acquired Pneumonia — all drugs for Community-acquired Pneumonia →
Sponsor
Henan University of Traditional Chinese Medicine
Who can join
65 and older, any sex, with Community-acquired Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the efficacy and safety of TCM syndrome differentiation treatment on the rehospitalization rate of discharged elderly patients with community acquired pneumonia(CAP)and to explore its mechanism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04702074
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Community-acquired Pneumonia
Currently open trials in the same condition.
- NCT07164131 — Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lacta · Phase 4 · recruiting
- NCT06577558 — Efficacy and Safety of SR1375 in Adult Patients With CAP · Phase 2 · recruiting
- NCT06229288 — Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, an · Phase 3 · recruiting
- NCT06125340 — Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy · Phase 4 · recruiting
- NCT06114888 — Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics · NA · recruiting
Other Henan University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
- NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
- NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
- NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
- NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04702074 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
- Last refreshed: 8 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04702074.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing